Endothelial Glycocalyx in Patients With Chronic Kidney Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

137 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-11-07

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The luminal side of the entire vasculature is covered with a gel-like polymer called endothelial glycocalyx (EG). EG is important for the transport of molecules in and out of the blood cells and for endothelial function. EG protects the blood vessel wall, is likely to contribute to maintenance of normal blood pressure and the prevention of blood clot formation. Overall it is likely to avoid development of cardiovascular disease.

A newly developed blood test, salt-blood test, can measure erythrocyte salt sensitivity and gives information about the condition of EG. EG can also be measured by release of endothelial glycocalyx proteins.

Previous studies indicate that this EG is impaired by a number of chronic diseases, including chronic kidney disease. This study investigates the quality of glycocalyx in patients with chronic kidney disease, and compares with the layer in healthy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dietary Interventions on Glycocalyx Dimensions in South Asian Patients With Diabetic Nephropathy.

NCT03889236

Diabetic Nephropathy Type 2 Albuminuria Type2 Diabetes Mellitus +7 more

COMPLETED NA

Soy Protein in Early Diabetic Nephropathy

NCT00067678

Diabetic Nephropathy Diabetes Mellitus

COMPLETED PHASE1/PHASE2

Effect of Probiotic Consumption on Chronic Kidney Disease

NCT03400228

Chronic Kidney Disease

COMPLETED NA

Effect of Oral Consumption of a Symbiotic Gelatin on the Presence of Gastrointestinal Symptoms and Quality of Life in People With Chronic Kidney Disease

NCT06745245

Chronic Kidney Disease(CKD) Dysbiosis Symptoms Linked to Pathology Probiotics Supplement

ACTIVE_NOT_RECRUITING NA

The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate

NCT01163162

Chronic Kidney Disease

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to gain knowledge about how pronounced the EG are affected in varying degrees of chronic kidney disease compared with healthy controls assessed by

1. salt-blood test
2. release of endothelial glycocalyx proteins.

and to see how this correlates to

1. blood pressure (peripheral and central)
2. pulse wave velocity
3. albuminuria
4. coagulation system
5. vasoactive hormones (PRC, p-Ang-II, p-Aldo, p-ANP, p-BNP, p-AVP)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Chronic Kidney Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CKD 1

Patients with Chronic kidney disease stage 1: Normal kidney function but urine findings or structural abnormalities or genetic trait point to kidney disease. eGFR :90+.

20 patients, maximun 4 patients with diabetes.